{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:25:20Z","timestamp":1790900720953,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.bpg.2005.04.001","type":"journal-article","created":{"date-parts":[[2005,10,25]],"date-time":"2005-10-25T12:44:45Z","timestamp":1130244285000},"page":"595-616","source":"Crossref","is-referenced-by-count":61,"title":["Peptide receptor radionuclide therapy"],"prefix":"10.1016","volume":"19","author":[{"given":"Jaap J.M.","family":"Teunissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dik J.","family":"Kwekkeboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Paul","family":"Esser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelf","family":"Valkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Krenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2005.04.001_bib1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib2","first-page":"1704","article-title":"Peptide receptor imaging and therapy","volume":"41","author":"Kwekkeboom","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib3","first-page":"2002","article-title":"Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-d-Phe1-octreotide","volume":"37","author":"Andersson","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib4","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1210\/en.136.9.3698","article-title":"Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide","volume":"136","author":"Hofland","year":"1995","journal-title":"Endocrinology"},{"key":"10.1016\/j.bpg.2005.04.001_bib5","first-page":"437","article-title":"Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy","volume":"58","author":"de Jong","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.bpg.2005.04.001_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience","volume":"32","author":"Valkema","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib7","first-page":"88","article-title":"In situ radiotherapy with 111In-pentetreotid. State of the art and perspectives","volume":"44","author":"McCarthy","year":"2000","journal-title":"Q J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","article-title":"Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-d-Phe1]-octreotide. A case history","volume":"733","author":"Krenning","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bpg.2005.04.001_bib9","first-page":"98","article-title":"Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide","volume":"44","author":"Capello","year":"2003","journal-title":"J Nucl Med"},{"issue":"supplement 2","key":"10.1016\/j.bpg.2005.04.001_bib10","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1023\/A:1027396313397","article-title":"Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy","volume":"10","author":"Krenning","year":"1999","journal-title":"Ann Oncol"},{"issue":"supplement 1","key":"10.1016\/j.bpg.2005.04.001_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000051858","article-title":"OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy","volume":"62","author":"Smith","year":"2000","journal-title":"Digestion"},{"key":"10.1016\/j.bpg.2005.04.001_bib12","first-page":"1902","article-title":"Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides","volume":"36","author":"O'Donoghue","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ijc.2910460315","article-title":"Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors","volume":"46","author":"Reubi","year":"1990","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bpg.2005.04.001_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/snuc.2002.31027","article-title":"Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings","volume":"32","author":"de Jong","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/snuc.2002.31565","article-title":"In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial","volume":"32","author":"Virgolini","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib16","first-page":"610","article-title":"Tumor response and clinical benefit in neuroendocrine tumors after 7.4GBq (90)Y-DOTATOC","volume":"43","author":"Waldherr","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00259-002-1050-8","article-title":"Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate","volume":"30","author":"Kwekkeboom","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bpg.2005.04.001_bib18","first-page":"1026","article-title":"Receptor-targeted radionuclide therapy using radiolabelled somatostatin analogues: tumour size versus curability","volume":"28","author":"de Jong","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib19","first-page":"1841","article-title":"Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size","volume":"42","author":"de Jong","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib20","first-page":"13S","article-title":"Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs","volume":"46","author":"de Jong","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib21","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1073\/pnas.90.9.4196","article-title":"Cloning and characterization of a fourth human somatostatin receptor","volume":"90","author":"Rohrer","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bpg.2005.04.001_bib22","first-page":"417","article-title":"Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28","volume":"45","author":"Panetta","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bpg.2005.04.001_bib23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1073\/pnas.89.1.251","article-title":"Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney","volume":"89","author":"Yamada","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bpg.2005.04.001_bib24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1006\/mcne.1993.1040","article-title":"Somatostatin teceptors: orphan that found family and function","volume":"4","author":"Bruno","year":"1993","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.bpg.2005.04.001_bib25","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1006\/bbrc.1993.2122","article-title":"Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype","volume":"195","author":"Yamada","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bpg.2005.04.001_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","article-title":"Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use","volume":"27","author":"Reubi","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib27","first-page":"1315","article-title":"Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-d-Phe1]octreotide in somatostatin receptor-positive organs","volume":"44","author":"Hofland","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/gut.38.1.33","article-title":"Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2","volume":"38","author":"John","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2005.04.001_bib29","doi-asserted-by":"crossref","unstructured":"Kwekkeboom DJ, Bakker WH, Kooij PP et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients 2001; 28: 1319\u20131325.","DOI":"10.1007\/s002590100574"},{"key":"10.1016\/j.bpg.2005.04.001_bib30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/snuc.2002.31769","article-title":"Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies","volume":"32","author":"Anthony","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib31","first-page":"1","article-title":"Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors","volume":"44","author":"Buscombe","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib32","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<767::AID-IJC17>3.0.CO;2-T","article-title":"Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver","volume":"81","author":"Slooter","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bpg.2005.04.001_bib33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(05)78355-0","article-title":"Yttrium-90-labelled somatostatin-analogue for cancer treatment","volume":"351","author":"Otte","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2005.04.001_bib34","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of [90Y-DOTA]-dPhe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study","volume":"12","author":"Waldherr","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bpg.2005.04.001_bib35","first-page":"S100","article-title":"Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors?","volume":"29","author":"Waldherr","year":"2002","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/snuc.2002.31563","article-title":"Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group","volume":"32","author":"Chinol","year":"2002","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/bip.10349","article-title":"90Y-DOTA-d-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies","volume":"66","author":"Paganelli","year":"2002","journal-title":"Biopolymers"},{"key":"10.1016\/j.bpg.2005.04.001_bib38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s002590100490","article-title":"Receptor-mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide","volume":"28","author":"Paganelli","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-002-1023-y","article-title":"Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study","volume":"30","author":"Bodei","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bpg.2005.04.001_bib40","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1007\/s00259-004-1571-4","article-title":"Receptor radionuclide therapy with (90)Y-[DOTA](0)-Tyr(3)-octreotide ((90)Y-DOTATOC) in neuroendocrine tumours","volume":"31","author":"Bodei","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"supplement 2","key":"10.1016\/j.bpg.2005.04.001_bib41","first-page":"S232","article-title":"Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with (90Y-DOTA0,Tyr3)octreotide in patients with somatostatin receptor positive tumours","volume":"30","author":"Valkema","year":"2003","journal-title":"Eur J Nucl Med"},{"issue":"supplement 2","key":"10.1016\/j.bpg.2005.04.001_bib42","first-page":"136P","article-title":"Survival in patients with neuroendocrine tumors after treatment with [90Y-DOTA,Tyr) in a phase-1 study","volume":"44","author":"Valkema","year":"2003","journal-title":"J Nucl Med"},{"issue":"supplement 2","key":"10.1016\/j.bpg.2005.04.001_bib43","first-page":"S238","article-title":"Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-Tyr3-octreotate (Y-90-DOTA-TATE) in patients with metastatic neuroendocrine tumors","volume":"31","author":"Baum","year":"2004","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib44","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s00761-004-0771-7","article-title":"Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren Klinischen Indikationen und Erfahrung mit 90Yttrium-markierten Somatostatinanaloga","volume":"10","author":"Baum","year":"2004","journal-title":"Der Onkologe"},{"issue":"supplement 2","key":"10.1016\/j.bpg.2005.04.001_bib45","first-page":"S231","article-title":"Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with neuroendocrine tumors: interim results","volume":"30","author":"Kwekkeboom","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bpg.2005.04.001_bib46","doi-asserted-by":"crossref","unstructured":"Kwekkeboom DJ, Teunissen JJ, Bakker WH et al. Radiolabelled somatostatin analog [177Lu-DOTAO, Tyr3]octreotate in patients with endocrine gastro entero pancreatic tumors. J Clin Oncol 2005; 23: 2754--2762.","DOI":"10.1200\/JCO.2005.08.066"},{"issue":"supplement","key":"10.1016\/j.bpg.2005.04.001_bib47","first-page":"33P","article-title":"Phase 1 study of therapy with 90Y-SMT487 (OctreoTher) in patients with somatostatin receptor (SS-R) positive tumors","volume":"43","author":"Valkema","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib48","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: first clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib49","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/0024-3205(91)90053-E","article-title":"In vivo application of [111In-DTPA-d-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats","volume":"49","author":"Bakker","year":"1991","journal-title":"Life Sci"},{"key":"10.1016\/j.bpg.2005.04.001_bib50","first-page":"652","article-title":"Somatostatin receptor scintigraphy with indium-111-DTPA-d-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide","volume":"33","author":"Krenning","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bpg.2005.04.001_bib52","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0272-6386(01)80135-9","article-title":"A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy","volume":"37","author":"Moll","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.bpg.2005.04.001_bib53","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s002590100599","article-title":"End-stage renal disease after treatment with 90Y-DOTATOC","volume":"28","author":"Cybulla","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib54","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/ndt\/16.5.1082","article-title":"Radiation nephropathy after radiotherapy in metastatic medullary thyroid carcinoma","volume":"16","author":"Stoffel","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bpg.2005.04.001_bib55","first-page":"99S","article-title":"Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose\u2013effect relationship","volume":"46","author":"Barone","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib56","first-page":"83S","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate","volume":"46","author":"Valkema","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib57","first-page":"1388","article-title":"Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo","volume":"37","author":"de Jong","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib58","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00259-003-1117-1","article-title":"86Y-DOTA0)-d-Phe1-Tyr3-octreotide (SMT487)\u2013a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion","volume":"30","author":"Jamar","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bpg.2005.04.001_bib59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00259-002-0982-3","article-title":"Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine","volume":"30","author":"Rolleman","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bpg.2005.04.001_bib60","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/ndt\/gfh362","article-title":"Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues","volume":"19","author":"Barone","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bpg.2005.04.001_bib61","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1089\/108497803322287664","article-title":"Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases","volume":"18","author":"Bushnell","year":"2003","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.bpg.2005.04.001_bib62","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.amjsurg.2004.01.019","article-title":"Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors","volume":"187","author":"Toth-Fejel","year":"2004","journal-title":"Am J Surg"},{"key":"10.1016\/j.bpg.2005.04.001_bib63","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00259-002-1107-8","article-title":"Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002","volume":"30","author":"de Jong","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bpg.2005.04.001_bib64","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1136\/bmj.317.7167.1191","article-title":"Reporting on quality of life in randomised controlled trials: bibliographic study","volume":"317","author":"Sanders","year":"1998","journal-title":"BMJ (Clin Res Ed.)"},{"key":"10.1016\/j.bpg.2005.04.001_bib65","first-page":"1556","article-title":"Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors","volume":"44","author":"Bushnell","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib66","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.2004.10.016","article-title":"Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate","volume":"22","author":"Teunissen","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bpg.2005.04.001_bib67","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1007\/s00259-003-1255-5","article-title":"DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals","volume":"30","author":"Wild","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"supplement 2","key":"10.1016\/j.bpg.2005.04.001_bib68","first-page":"S218","article-title":"Upregulation of gastrin and somatostatin receptor after irradiation","volume":"44","author":"B\u00e9h\u00e9","year":"2003","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.bpg.2005.04.001_bib69","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00259-003-1184-3","article-title":"Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting","volume":"30","author":"Reubi","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.bpg.2005.04.001_bib70","first-page":"2472","article-title":"A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer","volume":"9","author":"van Putten","year":"2003","journal-title":"Clin Cancer Res"}],"container-title":["Best Practice &amp; Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169180500065X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169180500065X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T13:37:26Z","timestamp":1586525846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169180500065X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S152169180500065X"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2005.04.001","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}